Baader Bank Aktiengesellschaft’s Atossa Therapeutics ATOS Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,424	Closed	-$7.77K	–	426
2025 Q4	$7.77K	Buy	+1,424	New	+$18K	﹤0.01%	430
2025 Q3	–	Sell	-667	Closed	-$5.13K	–	498
2025 Q2	$5.13K	Buy	+667	New	+$7.97K	﹤0.01%	430
2023 Q3	–	Sell	-724	Closed	-$10.6K	–	335
2023 Q2	$10.6K	Buy	+724	New	+$8.78K	﹤0.01%	376

Other funds holding ATOS

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Baader Bank Aktiengesellschaft's ATOS Position: Q1 2026 in Review

Baader Bank Aktiengesellschaft sold out of Atossa Therapeutics (ATOS) in Q1 2026, closing a stake of 1,424 shares — an estimated $7.77K sold.

Baader Bank Aktiengesellschaft first reported a position in ATOS in Q2 2023 and held it in 3 quarters. The position peaked at $10.6K in Q2 2023. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

Baader Bank Aktiengesellschaft reported no remaining Atossa Therapeutics position as of Q1 2026 after selling out during the quarter.
Baader Bank Aktiengesellschaft sold 1,424 Atossa Therapeutics shares in Q1 2026, an estimated $7.77K.
Baader Bank Aktiengesellschaft first reported a position in Atossa Therapeutics in Q2 2023 and held it in 3 quarters.
Baader Bank Aktiengesellschaft's Atossa Therapeutics position peaked at $10.6K in Q2 2023.
33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q1 2026, filed 8 May 2026.